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The mean day 7 TNFR1 ratio was 1.7 for patients with GVHD
0-1 (n50), 2.6 for patients with GVHD 2 (n19), and 3.1 for
patients with GVHD 3-4 (n13), p0.01.
We tested whether subjects whose day 7 TNFR1 ratio was in
the top quartile (day 7 TNFR1 ratio  2.5) were at increased
risk of developing GVHD 2-4, 1y TRM, and 1y survival com-
pared to subjects whose day 7 TNFR1 ratio was below the 75th
percentile. Subjects with day 7 TNFR1 ratios above 2.5 were
almost twice as likely to develop GVHD 2-4 and had an almost
50% increase in probability of death by 1 year. Because age is an
independent risk factor for GVHD, these results were compared
to a larger cohort of 355 adult patients (medain age 46.5y, range
18.3-65.2y) and a statistically signiﬁcant correlation between
TNFR1 day 7 ratios and GVHD 2-4, TRM and survival was
also observed [Table 1]. In additional analyses, TNFR1 day 7
ratios were an important predictor independent of donor
source.
We conclude that for children undergoing HSCT, the mag-
nitude of rise in TNFR1 after myeloablative transplant corre-
lates with the subsequent development of GVHD, TRM and
survival. These informative changes are detectable on day 7, up
to two weeks in advance of clinical manifestations of GVHD,
and may therefore be useful in developing of a predictive labo-
ratory test.
Table 1
TNFR1 Ratio
GVHD
2-4
1 YR
TRM
1 YR
Survival
Children (n82) Median age 8.8y (range 0.8-17.8y)
TNFR1 < 2.5 (n63) 33% 6% 77%
TNFR1 > 2.5 (n19) 58% 26% 53%
p0.02 p0.07 p0.04
Adults (n355) Median age 46.5y (range 18.3-65.2y)
TNFR1 < 2.5 (n264) 31% 19% 62%
TNFR1 > 2.5 (n91) 60% 41% 48%
p<0.001 p<0.001 p0.02
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POST-TRANSPLANTATION HIGH-DOSE CYCLOPHOSPHAMIDE (CY) IS EF-
FECTIVE SINGLE AGENT GVHD PROPHYLAXIS THAT PERMITS PROMPT
IMMUNE RECONSTITUTION AFTER MYELOABLATIVE HLA MATCHED RE-
LATED AND UNRELATED BONE MARROW TRANSPLANTATION (BMT)
Luznik, L.1, Fuchs, E.J.1, Chen, A.R.1, Kaup, M.1, Bright, E.C.1,
Bolanos-Meade, J.1, Hess, A.D.1, Jones, R.J.1 1Divsion of Hematologic
Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns
Hopkins, Baltimore, MD.
Prolonged pharmacologic immunosuppression is a major obstacle
to early immunologic recovery after allogeneic BMT. Based on our
results in animal models, we studied whether high dose Cy alone after
HLA-matched related or unrelated BMT is effective prophylaxis
against severe acute GVHD while permitting effective reconstitution
of lymphocytes, including regulatory T cells (Tregs). Forty-six consec-
utive patients (median age 41, range 1-64) with advanced hematologic
malignancies received HLA-matched related (n28) or unrelated
(n18) bonemarrow after conditioning with busulfan on days -7 to -3
and Cy (50 mg/kg/day) on days -2 and -1,3, and4. No additional
GVHD prophylaxis was administered. The cumulative incidence of
acute grades II-IV and grades III-IV GVHD were 41% and 9%,
respectively. Of the thirty-six patients alive after day 100, only 1 of the
23 patients that received HLA-matched related, and 3 of 13 patients
that received unrelated allografts, developed chronic GVHD. With a
median of 13 months (range 8-26 months) of follow-up, 26 (56%)
patients are alive, of whom 21 (45%) are in complete remission.
PBMCs collected at day 30-40, 40-60 and 60 post-transplant were
evaluated enumerating CD4Foxp3 cells by multi-color ﬂow-cy-
tometry and quantifying Foxp3, INF-, IL-2 and IL-10 mRNA tran-
scripts by quantitative PCR. Patients with grade II-IV acute GVHD
had signiﬁcantly fewer CD4Foxp3 T cells compared to patients
with grade 0-I GVHD (p0.05). Development of grade II-IV
GVHD negatively correlated with the expression of the Foxp3
(p0.05) and was associated with marginally higher expression of
INF- mRNA (p0.08) suggesting higher effector function in the
absence of Tregs in patients with grade II-IV GVHD. Expression of
IL-2 mRNA transcripts was signiﬁcantly higher in patients with grade
II-IVGVHD compared to patients with grade 0-I GVHD (p0.001).
Differences in IL-10 mRNA expression was not observed. These
results suggest that high-dose of post-transplantation Cy is effective as
a single agent for prevention of GVHD after HLA-matched related
or unrelated BMT. The rapid recovery of Tregs associated with this
strategy may also be responsible for the unexpectedly low incidence of
chronic GVHD; however, longer follow-up and larger numbers of
patients are needed.
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